Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?

@article{Becker2006RegulationOI,
  title={Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?},
  author={J. Becker and C. Delayre-Orthez and N. Frossard and F. Pons},
  journal={Fundamental \& Clinical Pharmacology},
  year={2006},
  volume={20}
}
Lung inflammatory diseases, such as acute lung injury (ALI), asthma, chronic obstructive pulmonary disease (COPD) and lung fibrosis, represent a major health problem worldwide. Although glucocorticoids are the most potent anti‐inflammatory drug in asthma, they exhibit major side effects and have poor activity in lung inflammatory disorders such as ALI or COPD. Therefore, there is growing need for the development of alternative or new therapies to treat inflammation in the lung. Peroxisome… Expand
Peroxisome proliferator-activated receptors as novel targets in lung disease.
TLDR
PPARs are novel targets for lung disease, and the continued work with PPAR agonists may result in a potential new treatment for these chronic inflammatory lung diseases. Expand
Peroxisome proliferator-activated receptors as novel targets in lung disease.
TLDR
PPARs are novel targets for lung disease, and the continued work with PPAR agonists may result in a potential new treatment for these chronic inflammatory lung diseases. Expand
Peroxisome Proliferator Activated Receptor Ligands as Regulators of Airway Inflammation and Remodelling in Chronic Lung Disease
TLDR
In murine models of allergen-induced inflammation, PPARα and PPARγ ligands reduce the influx of inflammatory cells, cytokine and mucus production, collagen deposition, and airways hyperresponsiveness, supporting the hypothesis that PPARs comprise additional therapeutic targets to mimimise the contribution of inflammation to airway remodelling and dysfunction. Expand
Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease
TLDR
Peroxisome proliferator‐activated receptors are novel targets for lung disease and continued work with these ligands may result in a potential new treatment for chronic inflammatory lung diseases. Expand
PPARs: Key Regulators of Airway Inflammation and Potential Therapeutic Targets in Asthma.
TLDR
Experimental findings strongly support the potential clinical benefits of PPAR agonists in the treatment of asthma and highlight PPARs' key role in asthma pathogenesis and their agonists' therapeutic potential. Expand
Regulation of peroxisome proliferator-activated receptor-alpha expression during lung inflammation.
TLDR
The data showed that PPARalpha is constitutively expressed in mouse lung and down-regulated in response to TNF-alpha or upon acute or allergic airway inflammation, which is inversely regulated with lung inflammation. Expand
Peroxisome proliferator-activated receptors: a therapeutic target in COPD?
TLDR
It is hypothesised that impaired peroxisome proliferator-activated receptor signalling may underlie some of the muscular disturbances in chronic obstructive pulmonary disease and the therapeutic potential of peroxISome proliferATOR- activated receptor modulation in the treatment of skeletal muscle dysfunction. Expand
Synergistic cycles of protease activity and inflammation via PPARγ degradation in chronic obstructive pulmonary disease
TLDR
A vicious cycle of mutual augmentation of protease activity and inflammation resulting from PPARγ degradation plays a role in the pathogenesis of COPD. Expand
Phytochemicals as Modulators of PPARs and RXRs
TLDR
The focus is then shifted to the findings on verbascoside, a phytochemical that exerts a strong anti-inflammatory activity against the development of experimental inflammatory bowel disease, and a comprehensive review of computational approaches to the discovery of phytochemicals for PPARα and PPARγ. Expand
PPARγ: Potential therapeutic target for ailments beyond diabetes and its natural agonism.
TLDR
The therapeutic significance of PPARγ for ailments other than diabetes is reviewed and natural molecules with potentialPPARγ agonistic activity are highlighted to prove beneficial for counteracting diseases by modulating PPARα activity through dietary changes. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 266 REFERENCES
PPAR-gamma agonists as therapy for diseases involving airway neutrophilia.
TLDR
If a peroxisome proliferator-activated receptor agonist has the same effect in man, and neutrophils are important in the progression of respiratory diseases, such as chronic obstructive pulmonary disease, then this class of compounds could be a potential therapy. Expand
PPAR‐γ agonists as therapy for diseases involving airway neutrophilia
TLDR
If a peroxisome proliferator-activated receptor agonist has the same effect in man, and neutrophils are important in the progression of respiratory diseases, such as chronic obstructive pulmonary disease, then this class of compounds could be a potential therapy. Expand
Peroxisome Proliferator-activated Receptor-γ as a Regulator of Lung Inflammation and Repair
TLDR
Evidence to date generally suggests that PPAR functions to dampen inflammation and injury in various animal models of acute lung injury and may also play an important role in other inflammatory/immune lung diseases, including ischemiareperfusion injury, allergic airway inflammation, and cancer. Expand
The role of PPARs in atherosclerosis.
TLDR
Experiments using animal models of atherosclerosis and clinical studies in humans strongly support an anti-atherosclerotic role for PPAR alpha and gamma in vivo, indicating that PPARs remain attractive therapeutic targets for the development of drugs used in the treatment of chronic inflammatory diseases such as Atherosclerosis. Expand
Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model.
TLDR
These results demonstrate that inhaled agonistic ligands of PPAR-gamma might have new therapeutic potential for airway asthmatic inflammation. Expand
Activation of Peroxisome Proliferator-Activated Receptors in Human Airway Smooth Muscle Cells Has a Superior Anti-inflammatory Profile to Corticosteroids: Relevance for Chronic Obstructive Pulmonary Disease Therapy 1
TLDR
A novel anti-inflammatory pathway in human airway smooth muscle is identified, where PPARγ activation has additional anti- inflammation effects to those of steroids, and PPAR ligands might act as potential treatments in human respiratory diseases. Expand
PPARα downregulates airway inflammation induced by lipopolysaccharide in the mouse
TLDR
The data clearly show that PPARα downregulates cell infiltration, chemoattractant production and enhanced MMP activity triggered by LPS in mouse lung, suggesting thatPPARα activation may have a beneficial effect in acute or chronic inflammatory airway disorders involving neutrophils and macrophages. Expand
Peroxisome Proliferator-Activated Receptor γ Regulates Eosinophil Functions: A New Therapeutic Target for Allergic Airway Inflammation
TLDR
It is shown that eosinophils, a major inflammatory cell in allergic inflammation, express PPARγ, a nuclear receptor that regulates lipid metabolism and glucose homeostasis and negatively modulates eOSinophil functions, such as survival, chemotaxis, antibody-dependent cellular cytotoxicity and degranulation. Expand
PPAR‐gamma modulates allergic inflammation through up‐regulation of PTEN
  • K. S. Lee, S. Park, +6 authors Yong Chul Lee
  • Medicine
  • FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • 2005
TLDR
A protective role of PPARγ is demonstrated in the pathogenesis of the asthma phenotype through regulation of PTEN expression throughregulation of phosphatase and tensin homologue deleted on chromosome ten. Expand
Peroxisome proliferator-activated receptor-{gamma} as a regulator of lung inflammation and repair.
TLDR
Evidence to date generally suggests that PPAR-gamma functions to dampen inflammation and injury in various animal models of acute lung injury and may also play an important role in other inflammatory/immune lung diseases, including ischemia-reperfusion injury, allergic airway inflammation, and cancer. Expand
...
1
2
3
4
5
...